AAHA's newly released 2026 Diabetes Management Guidelines for Dogs cover diagnosis, treatment, monitoring, and dietary ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the publication of 96-week data from its Phase 3 study of GENGLYCOS™ AAV gene therapy (pariglasgene brecaparvovec-opnr), also known as ...
Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune diseaseLISRAYA is a once-daily pill that directly targets ...
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating ...
Orsini, a leader in rare disease pharmacy solutions, announced today that it is a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral therapy for the treatment of ...
A prospective single‑arm observational cohort study published in Cardiology Discovery reports significant echocardiographic improvements and a low rate of mild short‑term adverse events after ...
Dietary habits, alcohol use, stress, poor sleep, and other habits can all contribute to high morning blood sugar. Here’s why, ...
Insulin, for many patients, is not just a medication; it is a marker of defeat. These beliefs are reinforced by family ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results